Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial

CONCLUSION: Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer.PMID:37079878 | DOI:10.1200/JCO.22.00577

Source: Clinical Genitourinary Cancer - April 20, 2023 Category: Cancer & Oncology Authors: Takuji Iwase Shigehira Saji Kotaro Iijima Kenji Higaki Shoichiro Ohtani Yasuyuki Sato Yasuo Hozumi Yoshie Hasegawa Yasuhiro Yanagita Hiroyuki Takei Maki Tanaka Hideji Masuoka Masahiko Tanabe Chiyomi Egawa Yoshifumi Komoike Toshitaka Nakamura Hiroshi Ohtsu Source Type: research